<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ajprenal.physiology.org">
<title>AJP: Renal Physiology current issue</title>
<link>http://ajprenal.physiology.org</link>
<description>AJP: Renal Physiology RSS feed -- current issue</description>
<prism:eIssn>1522-1466</prism:eIssn>
<prism:coverDisplayDate>May  1 2008 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>AJP: Renal Physiology</prism:publicationName>
<prism:issn>0363-6127</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1009?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1032?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/full/294/5/F1048?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1050?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1059?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1065?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1076?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1084?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1094?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1101?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1109?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1116?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1129?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1136?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1146?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1157?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1166?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1174?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1185?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1195?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1205?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1212?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1222?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1232?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1238?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1249?rss=1" />
  <rdf:li rdf:resource="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1257?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ajprenal.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ajprenal.physiology.org/icons/banner/title.gif">
<title>AJP: Renal Physiology</title>
<url>http://ajprenal.physiology.org/icons/banner/title.gif</url>
<link>http://ajprenal.physiology.org</link>
</image>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1009?rss=1">
<title><![CDATA[Acid-base analysis: a critique of the Stewart and bicarbonate-centered approaches]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1009?rss=1</link>
<description><![CDATA[ 
<P>When approaching the analysis of disorders of acid-base balance, physical chemists, physiologists, and clinicians, tend to focus on different aspects of the relevant phenomenology. The physical chemist focuses on a quantitative understanding of proton hydration and aqueous proton transfer reactions that alter the acidity of a given solution. The physiologist focuses on molecular, cellular, and whole organ transport processes that modulate the acidity of a given body fluid compartment. The clinician emphasizes the diagnosis, clinical causes, and most appropriate treatment of acid-base disturbances. Historically, two different conceptual frameworks have evolved among clinicians and physiologists for interpreting acid-base phenomena. The traditional or bicarbonate-centered framework relies quantitatively on the Henderson-Hasselbalch equation, whereas the Stewart or strong ion approach utilizes either the original Stewart equation or its simplified version derived by Constable. In this review, the concepts underlying the bicarbonate-centered and Stewart formulations are analyzed in detail, emphasizing the differences in how each approach characterizes acid-base phenomenology at the molecular level, tissue level, and in the clinical realm. A quantitative comparison of the equations that are currently used in the literature to calculate H<SUP>+</SUP> concentration ([H<SUP>+</SUP>]) is included to clear up some of the misconceptions that currently exist in this area. Our analysis demonstrates that while the principle of electroneutrality plays a central role in the strong ion formulation, electroneutrality mechanistically does not dictate a specific [H<SUP>+</SUP>], and the strong ion and bicarbonate-centered approaches are quantitatively identical even in the presence of nonbicarbonate buffers. Finally, our analysis indicates that the bicarbonate-centered approach utilizing the Henderson-Hasselbalch equation is a mechanistic formulation that reflects the underlying acid-base phenomenology.</P>
]]></description>
<dc:creator><![CDATA[Kurtz, I., Kraut, J., Ornekian, V., Nguyen, M. K.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00475.2007</dc:identifier>
<dc:title><![CDATA[Acid-base analysis: a critique of the Stewart and bicarbonate-centered approaches]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1031</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1009</prism:startingPage>
<prism:section>INVITED REVIEWS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1032?rss=1">
<title><![CDATA[PPARs and the kidney in metabolic syndrome]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1032?rss=1</link>
<description><![CDATA[ 
<P>The metabolic syndrome (MetS) is defined by a set of metabolic risk factors, including insulin resistance, central obesity, dyslipidemia, hyperglycemia, and hypertension for type 2 diabetes and cardiovascular disease. Although both retrospective and prospective clinical studies have revealed that MetS is associated with chronic renal disease, even with a nondiabetic cause, the cellular and molecular mechanisms in this association remain largely uncharacterized. Recently, increasing evidence suggests that peroxisome proliferator-activated receptors (PPARs), a subgroup of the nuclear hormone receptor superfamily of ligand-activated transcription factors, may play an important role in the pathogenesis of MetS. All three members of the PPAR nuclear receptor subfamily, PPAR, -&beta;/, and -, are critical in regulating insulin sensitivity, adipogenesis, lipid metabolism, inflammation, and blood pressure. PPARs have also been implicated in many renal pathophysiological conditions, including diabetic nephropathy and glomerulosclerosis. Ligands for PPARs such as hypolipidemic PPAR activators, and antidiabetic thiazolidinedione PPAR agonists affect not only diverse aspects of MetS but also renal disease progression. Emerging data suggest that PPARs may be potential therapeutic targets for MetS and its related renal complications. This review focuses on current knowledge of the role of PPARs in MetS and discusses the potential therapeutic utility of PPAR modulators in the treatment of kidney diseases associated with MetS.</P>
]]></description>
<dc:creator><![CDATA[Ruan, X., Zheng, F., Guan, Y.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00152.2007</dc:identifier>
<dc:title><![CDATA[PPARs and the kidney in metabolic syndrome]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1047</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1032</prism:startingPage>
<prism:section>INVITED REVIEWS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/full/294/5/F1048?rss=1">
<title><![CDATA[An expanding role of Toll-like receptors in sepsis-induced acute kidney injury]]></title>
<link>http://ajprenal.physiology.org/cgi/content/full/294/5/F1048?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Dagher, P. C., Basile, D. P.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00125.2008</dc:identifier>
<dc:title><![CDATA[An expanding role of Toll-like receptors in sepsis-induced acute kidney injury]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1049</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1048</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1050?rss=1">
<title><![CDATA[Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1050?rss=1</link>
<description><![CDATA[ 
<P>Mortality from sepsis has remained high despite recent advances in supportive and targeted therapies. Toll-like receptors (TLRs) sense bacterial products and stimulate pathogenic innate immune responses. Mice deficient in the common adapter protein MyD88, downstream from most TLRs, have reduced mortality and acute kidney injury (AKI) from polymicrobial sepsis. However, the identity of the TLR(s) responsible for the host response to polymicrobial sepsis is unknown. Here, we show that chloroquine, an inhibitor of endocytic TLRs (TLR3, 7, 8, 9), improves sepsis-induced mortality and AKI in a clinically relevant polymicrobial sepsis mouse model, even when administered 6 h after the septic insult. Chloroquine administration attenuated the decline in renal function, splenic apoptosis, serum markers of damage to other organs, and prototypical serum pro- and anti-inflammatory cytokines TNF- and IL-10. An oligodeoxynucleotide inhibitor (H154) of TLR9 and TLR9-deficient mice mirror the actions of chloroquine in all functional parameters that we tested. In addition, chloroquine decreased TLR9 protein abundance in spleen, further suggesting that TLR9 signaling may be a major target for the protective actions of chloroquine. Our findings indicate that chloroquine improves survival by inhibiting multiple pathways leading to polymicrobial sepsis and that chloroquine and TLR9 inhibitors represent viable broad-spectrum and targeted therapeutic strategies, respectively, that are promising candidates for further clinical development.</P>
]]></description>
<dc:creator><![CDATA[Yasuda, H., Leelahavanichkul, A., Tsunoda, S., Dear, J. W., Takahashi, Y., Ito, S., Hu, X., Zhou, H., Doi, K., Childs, R., Klinman, D. M., Yuen, P. S. T., Star, R. A.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00461.2007</dc:identifier>
<dc:title><![CDATA[Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1058</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1050</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1059?rss=1">
<title><![CDATA[Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1059?rss=1</link>
<description><![CDATA[ 
<P>Advanced glycation end products (AGEs), which are elevated in diabetic and uremic patients, may induce vascular dysfunctions, and calcitriol may improve the cardiovascular complications. Therefore, we examined whether calcitriol may modify the endothelial response to AGEs stimulation. Knowing the importance of nuclear factor-B in endothelial inflammatory responses, the effect of AGEs and calcitriol on this pathway was also studied. Calcitriol was added to endothelial cells previously incubated with AGE-human serum albumin (HSA). AGE-HSA induced a decrease in endothelial nitric oxide synthase (eNOS) mRNA expression and enzyme activity. Addition of calcitriol to AGE-HSA-treated endothelial cells improved the decreased action of AGEs on the eNOS system. AGE-HSA increased the AGEs receptor mRNA and protein, which were both blunted by calcitriol. The parallel elevation of interleukin-6 mRNA in the presence of AGE-HSA was also blunted by calcitriol. The NF-B-p65 DNA binding activity was enhanced and associated with a decrease in inhibitor B (IB) and an increase in phosphorylated (p)-IB levels. Addition of calcitriol blunted the AGEs-induced elevation of NF-B-p65 DNA binding activity, a phenomenon related to an increased expression of IB. This increase was correlated to declined p-IB levels. The present results support the concept that calcitriol may act as a vascular protective agent counteracting the probable deleterious actions of AGEs on endothelial cell activities.</P>
]]></description>
<dc:creator><![CDATA[Talmor, Y., Golan, E., Benchetrit, S., Bernheim, J., Klein, O., Green, J., Rashid, G.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00051.2008</dc:identifier>
<dc:title><![CDATA[Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1064</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1059</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1065?rss=1">
<title><![CDATA[High glucose-induced NF-{kappa}B activation occurs via tyrosine phosphorylation of I{kappa}B{alpha} in human glomerular endothelial cells: involvement of Syk tyrosine kinase]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1065?rss=1</link>
<description><![CDATA[ 
<P>Activation of nuclear factor-B (NF-B) occurs by dissociation from IB after serine or tyrosine phosphorylation of IB, but the way of NF-B activation by high glucose has not been defined. High glucose is known to activate NF-B via protein kinase C and reactive oxygen species (ROS). In this study, we investigated how high glucose activates NF-B for CC chemokine ligand 2 production in cultured human glomerular endothelial cells. High glucose increased nuclear translocation of p65 and also increased NF-B DNA binding activity. High glucose-induced NF-B activation occurred without degradation of IB. In agreement with this, there was no increase in serine phosphorylation of IB, while tyrosine phosphorylation of IB was increased by high glucose. High glucose increased the generation of ROS, whereas both -lipoic acid and <I>N</I>-acetylcysteine scavenged the ROS and decreased high glucose-induced tyrosine phosphorylation of IB, nuclear translocation of p65, and NF-B DNA binding activity. Protein kinase C pseudosubstrate inhibited high glucose-induced ROS production, tyrosine phosphorylation of IB, and nuclear translocation of p65. Both BAY 61-3606, a specific inhibitor of Syk protein-tyrosine kinase, and small interfering RNA directed against Syk inhibited high glucose-induced tyrosine phosphorylation of IB as well as p65 nuclear translocation. High glucose increased tyrosine phosphorylation of Syk, while it was inhibited by -lipoic acid and protein kinase C pseudosubstrate. In summary, high glucose-induced NF-B activation occurred not by serine phosphorylation of IB. Our data suggest that ROS-mediated tyrosine phosphorylation of IB is the mechanism for high glucose-induced NF-B activation, and Syk may play a role in tyrosine phosphorylation of IB.</P>
]]></description>
<dc:creator><![CDATA[Yang, W. S., Seo, J. W., Han, N. J., Choi, J., Lee, K.-U., Ahn, H., Lee, S. K., Park, S.-K.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00381.2007</dc:identifier>
<dc:title><![CDATA[High glucose-induced NF-{kappa}B activation occurs via tyrosine phosphorylation of I{kappa}B{alpha} in human glomerular endothelial cells: involvement of Syk tyrosine kinase]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1075</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1065</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1076?rss=1">
<title><![CDATA[Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1076?rss=1</link>
<description><![CDATA[ 
<P>Smad ubiquitination regulatory factor-2 (Smurf2) is an E3 ubiqutin ligase that plays a pivotal role in regulating TGF-&beta; signaling via selectively targeting key components of the Smad pathway for degradation. In this study, we have investigated the regulation of Smurf2 expression, its target specificity, and the functional implication of its induction in the fibrotic kidney. Immunohistochemical staining revealed that Smurf2 was upregulated specifically in renal tubules of kidney biopsies from patients with various nephropathies. In vitro, Smurf2 mRNA and protein were induced in human proximal tubular epithelial cells (HKC-8) upon TGF-&beta;1 stimulation. Ectopic expression of Smurf2 was sufficient to reduce the steady-state levels of Smad2, but not Smad1, Smad3, Smad4, and Smad7, in HKC-8 cells. Interestingly, Smurf2 was also able to downregulate the Smad transcriptional corepressors Ski, SnoN, and TG-interacting factor. Inhibition of the proteasomal pathway prevented Smurf2-mediated downregulation of Smad2 and Smad corepressors. Functionally, overexpression of Smurf2 enhanced the transcription of the TGF-&beta;-responsive promoter and augmented TGF-&beta;1-mediated E-cadherin suppression, as well as fibronectin and type I collagen induction in HKC-8 cells. These results indicate that Smurf2 specifically targets both positive and negative Smad regulators for destruction in tubular epithelial cells, thereby providing a complex fine-tuning of TGF-&beta; signaling. It appears that dysregulation of Smurf2 could contribute to an aberrant TGF-&beta;/Smad signaling in the pathogenesis of kidney fibrosis.</P>
]]></description>
<dc:creator><![CDATA[Tan, R., He, W., Lin, X., Kiss, L. P., Liu, Y.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00323.2007</dc:identifier>
<dc:title><![CDATA[Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1083</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1076</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1084?rss=1">
<title><![CDATA[Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1084?rss=1</link>
<description><![CDATA[ 
<P>Peritoneal fibrosis (PF) is an important complication of long-term peritoneal dialysis. Although mineralocorticoid and mineralocorticoid receptor (MR) have attracted increasing attention in the field of vascular injury, including the heart, kidney, and vessels, little is known about the role of mineralocorticoid in PF. This work was designed to explore the effects of MR blockade on PF. We developed a new model of PF in rats based on mechanical scraping of the peritoneum. This model is characterized by acute-phase inflammation (neutrophil and macrophage infiltration on <I>days 0&ndash;3</I>) and late-phase PF (-smooth muscle actin-positive fibroblast infiltration, type III collagen accumulation, and neoangiogenesis on <I>days 7&ndash;14</I>). Peritoneal thickening peaked on <I>day 14</I>. MR was expressed in rat peritoneum and a rat fibroblast cell line. Expression of its effector kinase [serum- and glucocorticoid-induced kinase-1 (Sgk1)], transforming growth factor-&beta; (TGF-&beta;), plasminogen activator inhibitor-1 (PAI-1), and CD31-positive vessels increased during the course of PF. Rats were treated with spironolactone, angiotensin receptor blockade (ARB), or angiotensin-converting enzyme inhibitor (ACEI)-ARB-spironolactone starting at 6 h after peritoneal scraping. All parameters, including peritoneal thickening, number of macrophages and CD31-positive vessels, and expression of monocyte chemoattractant protein-1, TGF-&beta;, PAI-1, and Sgk1, were significantly suppressed by spironolactone (10 mg&middot;kg<SUP>&ndash;1</SUP>&middot;day<SUP>&ndash;1</SUP>). The effects of spironolactone (10 and 20 mg&middot;kg<SUP>&ndash;1</SUP>&middot;day<SUP>&ndash;1</SUP>) were very similar to those of triple blockade. ARB, but not ACEI, significantly reduced peritoneal thickening. Furthermore, peritoneal function assessed by peritoneal equilibration test was significantly improved by spironolactone. Our results suggest that MR is a potential target to prevent inflammation-induced PF in patients on peritoneal dialysis.</P>
]]></description>
<dc:creator><![CDATA[Nishimura, H., Ito, Y., Mizuno, M., Tanaka, A., Morita, Y., Maruyama, S., Yuzawa, Y., Matsuo, S.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00565.2007</dc:identifier>
<dc:title><![CDATA[Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1093</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1084</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1094?rss=1">
<title><![CDATA[Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1094?rss=1</link>
<description><![CDATA[ 
<P>Maladaptive activation of the renin-angiotensin system (RAS) has been shown to play a critical role in the pathogenesis of chronic kidney disease. Reactive oxygen species (ROS) are critical signals for many of the nonhemodynamic effects of angiotensin II (ANG II). We have demonstrated that ANG II increases mesangial and cortical cyclooxygenase-2 (COX-2) expression and activity via NADPH oxidase-derived ROS. The transcription factor ETS-1 (E26 transformation-specific sequence) has been identified as a critical regulator of growth-related responses and inflammation. The present studies were designed to determine: <I>1</I>) whether ANG II induces ETS-1 expression in vitro in cultured rat mesangial cells and in vivo in rats infused with ANG II; and <I>2</I>) whether ROS and COX-2 are mediators of ETS-1 induction in response to ANG II. Mesangial cells stimulated with ANG II (10<SUP>&ndash;7</SUP> M) exhibited a significant increase in ETS-1 expression that was prevented by the angiotensin type 1 receptor blocker candesartan. NADPH oxidase inhibition with dyphenilene iodinium or apocynin also prevented ETS-1 induction, establishing the role of ROS as mediators of ETS-1 expression in response to ANG II. COX-2 inhibition prevented ETS-1 expression in response to ANG II, suggesting that COX-2 is required for ETS-1 induction. By utilizing short interfering RNAs against ETS-1, we have also determined that ETS-1 is required to induce the production of fibronectin in response to ANG II. Furthermore, rats infused with ANG II manifested increased glomerular expression of ETS-1. These studies unveil novel pathways that may play an important role in the pathogenesis of renal injury when RAS is activated.</P>
]]></description>
<dc:creator><![CDATA[Pearse, D. D., Tian, R.-X., Nigro, J., Iorgulescu, J. B., Puzis, L., Jaimes, E. A.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00458.2007</dc:identifier>
<dc:title><![CDATA[Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1100</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1094</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1101?rss=1">
<title><![CDATA[Identification and subcellular localization of a new cystinosin isoform]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1101?rss=1</link>
<description><![CDATA[ 
<P>Nephropathic cystinosis is a lysosomal disorder caused by functional defects of cystinosin, which mediates cystine efflux into the cytosol. The protein sequence contains at least two signals that target the protein to the lysosomal compartment, one of which is located at the carboxy terminal tail (GYDQL). We have isolated from a human kidney cDNA library a cystinosin isoform, which is generated by an alternative splicing of exon 12 that removes the GYDQL motif. Based on its last three amino acids, we have termed this protein cystinosin-LKG. Contrary to the lysosomal cystinosin isoform, expression experiments performed by transient transfection of green fluorescent protein fusion plasmids in HK2 cells showed that cystinosin-LKG is expressed in the plasma membrane, in lysosomes, and in other cytosolic structures. This subcellular localization of the protein was confirmed by transmission electron microscopy. In addition, immunogold labeling was observed in the endoplasmic reticulum and in the Golgi apparatus. Expression of the protein in renal tubular structures was also directly demonstrated by immunostaining of normal human kidney sections. The plasma membrane localization of cystinosin-LKG was directly tested by [<SUP>35</SUP>S]cystine flux experiments in COS-1 cells. In the presence of a proton gradient, a marked enhancement of intracellular cystine transport was observed in cells overexpressing this isoform. These data indicate that the expression of the gene products encoded by the CTNS gene is not restricted to the lysosomal compartment. These finding may help elucidate the mechanisms of cell dysfunction in this disorder.</P>
]]></description>
<dc:creator><![CDATA[Taranta, A., Petrini, S., Palma, A., Mannucci, L., Wilmer, M. J., De Luca, V., Diomedi-Camassei, F., Corallini, S., Bellomo, F., van den Heuvel, L. P., Levtchenko, E. N., Emma, F.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00413.2007</dc:identifier>
<dc:title><![CDATA[Identification and subcellular localization of a new cystinosin isoform]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1108</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1101</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1109?rss=1">
<title><![CDATA[Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1109?rss=1</link>
<description><![CDATA[ 
<P>The most common theories about the pathogenesis of idiopathic kidney stones consider precipitation of calcium phosphate (CaP) within the kidneys critical for the development of the disease. We decided to test the hypothesis that a CaP substrate can promote the deposition of calcium oxalate (CaOx) in the kidneys. Experimental hyperoxaluria was induced by feeding glyoxylate to male mice with knockout (KO) of NaP<SUB>i</SUB> IIa (Npt2a), a sodium-phosphate cotransporter. Npt2a KO mice are hypercalciuric and produce CaP deposits in their renal tubules. Experimental hyperoxaluria led to CaOx crystalluria in both the hypercalciuric KO mice and the normocalciuric control B6 mice. Only the KO mice produced CaOx crystal deposits in their kidneys, but the CaOx crystals deposited separately from the CaP deposits. Perhaps CaP deposits were not available for a CaOx overgrowth. These results also validate earlier animal model observations that showed that CaP substrate is not required for renal deposition of CaOx and that other factors, such as local supersaturation, may be involved. The absence of CaOx deposition in the B6 mice despite extreme hyperoxaluria also signifies the importance of both calcium and oxalate in the development of CaOx nephrolithiasis.</P>
]]></description>
<dc:creator><![CDATA[Khan, S. R., Glenton, P. A.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00620.2007</dc:identifier>
<dc:title><![CDATA[Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1115</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1109</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1116?rss=1">
<title><![CDATA[MKL1 mediates TGF-{beta}1-induced {alpha}-smooth muscle actin expression in human renal epithelial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1116?rss=1</link>
<description><![CDATA[ 
<P>Transforming growth factor-&beta;1 (TGF-&beta;1) is known to induce epithelial-mesenchymal transition in the kidney, a process involved in tubulointerstitial fibrosis. We hypothesized that a coactivator of the serum response factor (SRF), megakaryoblastic leukemia factor-1 (MKL1), stimulates -smooth muscle actin (-SMA) transcription in primary cultures of renal tubular epithelial cells (RTC), which convert into myofibroblasts on treatment with TGF-&beta;1. Herein, we study the effect of MKL1 expression on -SMA in these cells. We demonstrate that TGF-&beta;1 stimulation of -SMA transcription is mediated through CC(A/T)<SUB>6</SUB>-rich GG elements known to bind to SRF. These elements also mediate the MKL1 effect that dramatically activates -SMA transcription in serum-free media. MKL1 fused to green fluorescent protein localizes to the nucleus and induces -SMA expression regardless of treatment with TGF-&beta;1. Using proteasome inhibitors, we also demonstrate that the proteolytic ubiquitin pathway regulates MKL1 expression. These data indicate that MKL1 overexpression is sufficient to induce -SMA expression. Inhibition of endogenous expression of MKL1 by small interfering RNA abolishes TGF-&beta;1 stimulation of -SMA expression. Therefore, MKL1 is also absolutely required for TGF-&beta;1 stimulation of -SMA expression. Western blot and immunofluorescence analysis show that overexpressed and endogenous MKL1 are located in the nucleus in non-stimulated RTC. Chromatin immunoprecipitation assay demonstrates that TGF-&beta;1 induces binding of endogenous SRF and MKL1 to the -SMA promoter in chromatin. Since MKL1 constitutes a potent factor regulating -SMA expression, modulation of endogenous MKL1 expression or activity may have a profound effect on myofibroblast formation and function in the kidney.</P>
]]></description>
<dc:creator><![CDATA[Elberg, G., Chen, L., Elberg, D., Chan, M. D., Logan, C. J., Turman, M. A.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00142.2007</dc:identifier>
<dc:title><![CDATA[MKL1 mediates TGF-{beta}1-induced {alpha}-smooth muscle actin expression in human renal epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1128</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1116</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1129?rss=1">
<title><![CDATA[Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1129?rss=1</link>
<description><![CDATA[ 
<P>Interstitial cystitis (IC) is associated with increased activated mast cell numbers in the bladder and impairment of the barrier function of the urothelium. We stimulated immortalized urothelial cells derived from the inflamed region of IC bladders (SR22A or SM28 abn) or from healthy bladders (PD07i or PD08i) with tryptase and measured phospholipase A<SUB>2</SUB> (PLA<SUB>2</SUB>) activity and the resultant release of arachidonic acid and prostaglandin E<SUB>2</SUB> (PGE<SUB>2</SUB>). Tryptase stimulation of either PD07i or SR22A resulted in similar increases in PLA<SUB>2</SUB> activity and arachidonic acid release. However, tryptase stimulation of SR22A and SM28 abn did not result in a significant increase in PGE<SUB>2</SUB> release compared with the increase in PGE<SUB>2</SUB> release from tryptase-stimulated PD07i and PD08i cells. Expression of mRNA for cyclooxygenase-2 and PGE synthase was lower and mRNA for 15-hydroxyprostaglandin dehydrogenase was higher in SR22A compared with PD07i, suggesting that both decreased synthesis and increased metabolism are responsible for the lack of a PGE<SUB>2</SUB> response in tryptase-stimulated SR22A cells. Since PGE<SUB>2</SUB> is a cytoprotective eicosanoid, the failure to produce this metabolite in cells isolated from the IC bladder may represent an increased susceptibility to damage by proinfammatory stimuli.</P>
]]></description>
<dc:creator><![CDATA[Rastogi, P., Rickard, A., Dorokhov, N., Klumpp, D. J., McHowat, J.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00572.2007</dc:identifier>
<dc:title><![CDATA[Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1135</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1129</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1136?rss=1">
<title><![CDATA[LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1136?rss=1</link>
<description><![CDATA[ 
<P>The early nephropathy in obese, diabetic, dyslipidemic (ZS) rats is characterized by tubular lipid accumulation and pervasive inflammation, two critically interrelated events. We now tested the hypothesis that proximal tubules from ZS obese diabetic rats in vivo, and proximal tubule cells (NRK52E) exposed to oxidized LDL (oxLDL) in vitro, change their normally quiescent epithelial phenotype into a proinflammatory phenotype. Urine of obese diabetic rats contained more lipid peroxides, and LOX-1, a membrane receptor that internalizes oxidized lipids, was mobilized to luminal sites. Levels of ICAM-1 and focal adhesion kinase, which participate in leukocyte migration and epithelial dedifferentiation, respectively, were also upregulated in tubules. NRK52E cells exposed to oxLDL showed similar modifications, plus suppression of anti-inflammatory transcription factor peroxisome proliferator-activated receptor-. In addition, oxLDL impaired epithelial barrier function. These alterations were prevented by an anti-LOX-1 antibody. The data support the concept that tubular LOX-1 activation driven by lipid oxidants in the preurine fluid is critical in the inflammatory changes. We suggest that luminal lipid oxidants and abnormal tubular permeability may be partly responsible for the renal tubulointerstitial injury of obesity, diabetes, and dyslipidemia.</P>
]]></description>
<dc:creator><![CDATA[Kelly, K. J., Wu, P., Patterson, C. E., Temm, C., Dominguez, J. H.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00396.2007</dc:identifier>
<dc:title><![CDATA[LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1145</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1136</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1146?rss=1">
<title><![CDATA[Sensitization of pelvic afferent nerves in the in vitro rat urinary bladder-pelvic nerve preparation by purinergic agonists and cyclophosphamide pretreatment]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1146?rss=1</link>
<description><![CDATA[ 
<P>Effects of purinergic agonists (,&beta;-meATP and ATP) and cyclophosphamide-induced cystitis on bladder afferent nerve (BAN) activity were studied in an in vitro bladder-pelvic nerve preparation. Distension of the bladder induced spontaneous bladder contractions that were accompanied by multiunit afferent firing. Intravesical administration of 40 and 130 &micro;M ,&beta;-meATP increased afferent firing from 27 &plusmn; 3 to 53 &plusmn; 6 and 61 &plusmn; 2 spikes/s, respectively, but did not change the maximum amplitude of spontaneous bladder contractions. Electrical stimulation on the surface of the bladder elicited action potentials (AP) in BAN. ,&beta;-meATP decreased the voltage threshold from 9.0 &plusmn; 1.2 to 3.5 &plusmn; 0.5 V (0.15-ms pulse duration) and increased the area of the APs (82% at 80-V stimulus intensity). These effects were blocked by TNP-ATP (30 &micro;M). ATP (2 mM) applied in the bath produced similar changes in BAN activity. These effects were blocked by bath application of PPADS (30 &micro;M). Neither TNP-ATP nor PPADS affected BAN activity induced by distension of the bladder. Cystitis induced by pretreatment of the rats with cyclophosphamide (100 mg/kg ip) increased afferent firing in response to isotonic bladder distension (10&ndash;40 cmH<SUB>2</SUB>O), decreased the threshold, and increased the area of evoked APs. The increase in afferent firing at 10 cmH<SUB>2</SUB>O intravesical pressure was reduced 52% by PPADS. These results indicate that purinergic agonists acting on P2X receptors and cystitis induced by cyclophosphamide can increase excitability of the BANs.</P>
]]></description>
<dc:creator><![CDATA[Yu, Y., de Groat, W. C.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00592.2007</dc:identifier>
<dc:title><![CDATA[Sensitization of pelvic afferent nerves in the in vitro rat urinary bladder-pelvic nerve preparation by purinergic agonists and cyclophosphamide pretreatment]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1156</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1146</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1157?rss=1">
<title><![CDATA[Nedd4-2 isoforms ubiquitinate individual epithelial sodium channel subunits and reduce surface expression and function of the epithelial sodium channel]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1157?rss=1</link>
<description><![CDATA[ 
<P>We previously reported the existence of multiple isoforms of human Nedd4-2 (<I>Am J Physiol Renal Physiol</I> 285: F916&ndash;F929, 2003). When overexpressed in M-1 collecting duct epithelia, full-length Nedd4-2 (Nedd4-2), Nedd4-2 lacking the NH<SUB>2</SUB>-terminal C2 domain (Nedd4-2C2), and Nedd4-2 lacking WW domains 2 and 3 (Nedd4-2WW2,3) variably reduce benzamil-sensitive Na<SUP>+</SUP> transport. We investigated the effect of each of the Nedd4-2 isoforms on cell surface expression and ubiquitination of ENaC subunits. We find that ENaC when transfected alone or with &beta; and ENaC is expressed at the cell surface and this membrane expression is variably reduced by coexpression with each of the Nedd4-2 isoforms. Nedd4-2 reduces the half-life of ENaC subunits and enhances the ubiquitination of , &beta;, and ENaC subunits when expressed alone or together suggesting that each subunit is a target for Nedd4-2-mediated ubiquitination. As has been reported recently, we confirm that the surface-expressed pool of ENaC is multi-ubiquitinated. Inhibitors of the proteasome increase ubiquitination of ENaC subunits and stimulate Na<SUP>+</SUP> transport in M-1 cells consistent with a role for the ubiquitin-proteasome pathway in regulating Na<SUP>+</SUP> transport in the collecting duct.</P>
]]></description>
<dc:creator><![CDATA[Raikwar, N. S., Thomas, C. P.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00339.2007</dc:identifier>
<dc:title><![CDATA[Nedd4-2 isoforms ubiquitinate individual epithelial sodium channel subunits and reduce surface expression and function of the epithelial sodium channel]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1165</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1157</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1166?rss=1">
<title><![CDATA[Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1166?rss=1</link>
<description><![CDATA[ 
<P>Previously, we have reported that pigment epithelium-derived factor (PEDF) ameliorates albuminuria and inhibits matrix protein deposition in the kidney of streptozotocin (STZ)-induced diabetic rats, suggesting a renoprotective effect of PEDF in early stages of diabetic nephropathy. As inflammation is a major contributor to the development and progression of diabetic nephropathy, we examined in the present study whether PEDF inhibits renal inflammation in diabetic kidney. Diabetic rats received an intravenous injection of an adenovirus expressing PEDF (Ad-PEDF) or the same titer of a control virus. Three wk after the injection, diabetic rats treated with the control virus showed significantly elevated renal levels of proinflammatory factors such as ICAM-1, MCP-1, TNF-, and VEGF compared with age-matched nondiabetic controls. Ad-PEDF effectively suppressed the overexpression of these proinflammatory factors in diabetic kidneys. In cultured primary human renal mesangial cells (HMC), the high-glucose medium-induced upregulation of VEGF and MCP-1 was largely blocked by PEDF. Furthermore, PEDF inhibited high glucose-induced activation of NF-B, a key transcription factor mediating inflammatory responses, and hypoxia-inducible factor-1, a major activator of VEGF expression in HMC. These results suggest that the renoprotective effect of PEDF against diabetic nephropathy may be partially through its anti-inflammatory activity, likely by blocking the NF-B and HIF-1 pathways.</P>
]]></description>
<dc:creator><![CDATA[Wang, J. J., Zhang, S. X., Mott, R., Chen, Y., Knapp, R. R., Cao, W., Ma, J.-x.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00375.2007</dc:identifier>
<dc:title><![CDATA[Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1173</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1166</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1174?rss=1">
<title><![CDATA[Angiopoietin 1 and 2 gene and protein expression is differentially regulated in acute anti-Thy1.1 glomerulonephritis]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1174?rss=1</link>
<description><![CDATA[ 
<P>Capillary neoformation is important in repair of glomerular injury of various origins. VEGF was shown to be crucial for glomerular capillary repair in glomerulonephritis (GN). We reasoned that other angiogenic factors are likewise involved in glomerular capillary remodeling and found angiopoietin 1 and -2 (ANG1 and ANG2) mRNA to be upregulated in cDNA microarrays of microdissected glomeruli of anti-Thy1.1 GN of the rat. We then studied glomerular in situ gene and protein expression of ANG1 and ANG2 and their receptor Tie-2 in the course of anti-Thy1.1 GN, which was induced by injection of OX-7 antibody. Animals were perfusion fixed at <I>days 6</I> and <I>12</I> after GN induction and compared with nonnephritic controls receiving PBS. Capillary damage and repair were quantitatively analyzed using stereological techniques. Gene and protein expression of ANG1 and ANG2 and their receptor Tie-2 was analyzed using real-time quantitative PCR from microdissected glomeruli, nonradioactive in situ hybridization, double immunofluorescence, and Western blot analysis. Glomerular capillarization assessed as length density was significantly lower at <I>day 6</I> of anti-Thy1.1 GN than in controls; it was back to normal values at <I>day 12</I>. ANG1 and ANG2 gene expression was markedly upregulated at <I>day 6</I> of the disease compared with controls. Protein expression of ANG1 and ANG2 was confined to podocytes and that of Tie-2 to endothelial cells. At <I>day 12</I> of anti-Thy1.1 GN when capillary restoration was nearly completed, ANG1 and ANG2 gene expression returned to basal levels, whereas Tie-2 expression was still high. With the use of a combined molecular and in situ approach, the spatial and temporal gene and protein expression of the angiopoietins and their receptor was analyzed in anti-Thy1.1 GN. The results indicate that glomerular expression of ANG1 and ANG2 and Tie-2 is differentially regulated and may contribute to healing and endothelial cell stabilization in experimental GN.</P>
]]></description>
<dc:creator><![CDATA[Campean, V., Karpe, B., Haas, C., Atalla, A., Peters, H., Rupprecht, H., Liebner, S., Acker, T., Plate, K., Amann, K.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00320.2007</dc:identifier>
<dc:title><![CDATA[Angiopoietin 1 and 2 gene and protein expression is differentially regulated in acute anti-Thy1.1 glomerulonephritis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1184</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1174</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1185?rss=1">
<title><![CDATA[Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1185?rss=1</link>
<description><![CDATA[ 
<P>In preeclampsia (PE), proteinuria has been associated with a reduced expression of nephrin by podocytes. In the present study, we investigated in vitro on human cultured podocytes the mechanism responsible for nephrin loss in PE. Sera from patients with PE did not directly downregulate the expression of nephrin. In contrast, conditioned medium obtained from glomerular endothelial cells incubated with PE sera induced loss of nephrin and synaptopodin, but not of podocin, from podocytes. Nephrin loss was related to a rapid shedding of the protein from the cell surface due to cleavage of its extracellular domain by proteases and to cytoskeleton redistribution. The absence of nephrin mRNA downregulation together with nephrin reexpression within 24 h confirm that the loss of nephrin was not related to a reduced synthesis. Studies with an endothelin-1 (ET-1) receptor antagonist that abrogated the loss of nephrin triggered by glomerular endothelial conditioned medium of PE sera indicated that ET-1 was the main effector of nephrin loss. Indeed, ET-1 was synthesized and released from glomerular endothelial cells when incubated with PE sera, and recombinant ET-1 triggered nephrin shedding from podocytes. Moreover, VEGF blockade induced ET-1 release from endothelial cells, and in turn the conditioned medium obtained triggered nephrin loss. In conclusion, the present study identifies a potential mechanism of nephrin loss in PE that may link endothelial injury with enhanced glomerular permeability.</P>
]]></description>
<dc:creator><![CDATA[Collino, F., Bussolati, B., Gerbaudo, E., Marozio, L., Pelissetto, S., Benedetto, C., Camussi, G.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00442.2007</dc:identifier>
<dc:title><![CDATA[Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1194</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1185</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1195?rss=1">
<title><![CDATA[Nicotine-activated descending facilitation on spinal NMDA-dependent reflex potentiation from pontine tegmentum in rats]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1195?rss=1</link>
<description><![CDATA[ 
<P>This study was conducted to investigate the possible neurotransmitter that activates the descending pathways coming from the dorsolateral pontine tegmentum (DPT) to modulate spinal pelvic-urethra reflex potentiation. External urethra sphincter electromyogram (EUSE) activity in response to test stimulation (TS, 1/30 Hz) and repetitive stimulation (RS, 1 Hz) on the pelvic afferent nerve of 63 anesthetized rats were recorded with or without microinjection of nicotinic cholinergic receptor (nAChR) agonists, ACh and nicotine, to the DPT. TS evoked a baseline reflex activity with a single action potential (1.00 &plusmn; 0.00 spikes/stimulation, <I>n</I> = 40), whereas RS produced a long-lasting reflex potentiation (16.14 &plusmn; 0.96 spikes/stimulation, <I>n</I> = 40) that was abolished by <SCP>d</SCP>-2-amino-5-phosphonovaleric acid (1.60 &plusmn; 0.89 spikes/stimulation, <I>n</I> = 40) and was attenuated by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F) quinoxaline (7.10 &plusmn; 0.84 spikes/stimulation, <I>n</I> = 40). ACh and nicotine microinjections to DPT both produced facilitation on the RS-induced reflex potentiation (23.57 &plusmn; 2.23 and 28.29 &plusmn; 2.36 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 10 and 20, respectively). Pretreatment of selective nicotinic receptor antagonist, chlorisondamine, reversed the facilitation on RS-induced reflex potentiation caused by nicotine (19.41 &plusmn; 1.21 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 10) Intrathecal WAY-100635 and spinal transection at the T<SUB>1</SUB> level both abolished the facilitation on reflex potentiation resulting from the DPT nicotine injection (12.86 &plusmn; 3.13 and 15.57 &plusmn; 1.72 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 10 each). Our findings suggest that activation of nAChR at DPT may modulate <I>N</I>-methyl-<SCP>d</SCP>-aspartic acid-dependent reflex potentiation via descending serotonergic neurotransmission. This descending modulation may have physiological/pathological relevance in the neural controls of urethral closure.</P>
]]></description>
<dc:creator><![CDATA[Pan, S.-F., Peng, H.-Y., Chen, C.-C., Chen, M.-J., Lee, S.-D., Cheng, C.-L., Shyu, J.-C., Liao, J.-M., Chen, G.-D., Lin, T.-B.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00539.2007</dc:identifier>
<dc:title><![CDATA[Nicotine-activated descending facilitation on spinal NMDA-dependent reflex potentiation from pontine tegmentum in rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1204</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1195</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1205?rss=1">
<title><![CDATA[Renal medullary ETB receptors produce diuresis and natriuresis via NOS1]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1205?rss=1</link>
<description><![CDATA[ 
<P>Endothelin-1 (ET-1) plays an important role in the regulation of salt and water excretion in the kidney. Considerable in vitro evidence suggests that the renal medullary ET<SUB>B</SUB> receptor mediates ET-1-induced inhibition of electrolyte reabsorption by stimulating nitric oxide (NO) production. The present study was conducted to test the hypothesis that NO synthase 1 (NOS1) and protein kinase G (PKG) mediate the diuretic and natriuretic effects of ET<SUB>B</SUB> receptor stimulation in vivo. Infusion of the ET<SUB>B</SUB> receptor agonist sarafotoxin S6c (S6c: 0.45 &micro;g&middot;kg<SUP>&ndash;1</SUP>&middot;h<SUP>&ndash;1</SUP>) in the renal medulla of anesthetized, male Sprague-Dawley rats markedly increased the urine flow (UV) and urinary sodium excretion (UNaV) by 67 and 120%, respectively. This was associated with an increase in medullary cGMP content but did not affect blood pressure. In addition, S6c-induced diuretic and natriuretic responses were absent in ET<SUB>B</SUB> receptor-deficient rats. Coinfusion of <I>N</I><SUP>G</SUP>-propyl-<SCP>l</SCP>-arginine (10 &micro;g&middot;kg<SUP>&ndash;1</SUP>&middot;h<SUP>&ndash;1</SUP>), a selective NOS1 inhibitor, suppressed S6c-induced increases in UV, UNaV, and medullary cGMP concentrations. Rp-8-Br-PET-cGMPS (10 &micro;g&middot;kg<SUP>&ndash;1</SUP>&middot;h<SUP>&ndash;1</SUP>) or RQIKIWFQNRRMKWKK-LRK<SUB>5</SUB>H-amide (18 &micro;g&middot;kg<SUP>&ndash;1</SUP>&middot;h<SUP>&ndash;1</SUP>), a PKG inhibitor, also inhibited S6c-induced increases in UV and UNaV. These results demonstrate that renal medullary ET<SUB>B</SUB> receptor activation induces diuretic and natriuretic responses through a NOS1, cGMP, and PKG pathway.</P>
]]></description>
<dc:creator><![CDATA[Nakano, D., Pollock, J. S., Pollock, D. M.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00578.2007</dc:identifier>
<dc:title><![CDATA[Renal medullary ETB receptors produce diuresis and natriuresis via NOS1]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1211</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1205</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1212?rss=1">
<title><![CDATA[Protein kinase C inhibits caveolae-mediated endocytosis of TRPV5]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1212?rss=1</link>
<description><![CDATA[ 
<P>Transient receptor potential vanilloid 5 (TRPV5) constitutes the apical entry pathway for transepithelial Ca<SUP>2+</SUP> reabsorption in kidney. Many hormones alter renal Ca<SUP>2+</SUP> reabsorption at least partly by regulating TRPV5. The mechanism for acute regulation of TRPV5 by phospholipase C-coupled hormones is largely unknown. Here, we found that protein kinase C (PKC) activator 1-oleoyl-acetyl-sn-glycerol (OAG) increased TRPV5 current density and surface abundance in cultured cells. The OAG-mediated increase of TRPV5 was prevented by preincubation with specific PKC inhibitors. Coexpression with a dominant-negative dynamin increased the basal TRPV5 current density and prevented the increase by OAG. Knockdown of caveolin-1 by small interference RNA (siRNA) prevented the increase of TRPV5 by OAG. In contrast, knockdown of clathrin heavy chain had no effects. OAG had no effect on TRPV5 expressed in caveolin-1 null cells derived from caveolin-1 knockout mice. Forced expression of recombinant caveolin-1 restored the regulation of TRPV5 by OAG in caveolin-1 knockout cells. Mutations of serine-299 and/or serine-654 of TRPV5 (consensus residues for phosphorylation by PKC) abolished the regulation by OAG. Parathyroid hormone (PTH) increased TRPV5 current density in cells coexpressing TRPV5 and type 1 PTH receptor. The increase caused by PTH was prevented by PKC inhibitor, mutation of serine-299/serine-654, or by knockdown of caveolin-1. Thus, TRPV5 undergoes constitutive caveolae-mediated endocytosis. Activation of PKC increases cell surface abundance of TRPV5 by inhibiting the endocytosis. This mechanism of regulation by PKC may contribute to the acute stimulation of TRPV5 and renal Ca<SUP>2+</SUP> reabsorption by PTH.</P>
]]></description>
<dc:creator><![CDATA[Cha, S.-K., Wu, T., Huang, C.-L.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00007.2008</dc:identifier>
<dc:title><![CDATA[Protein kinase C inhibits caveolae-mediated endocytosis of TRPV5]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1221</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1212</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1222?rss=1">
<title><![CDATA[Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1222?rss=1</link>
<description><![CDATA[ 
<P>The obese Zucker rat reportedly has increased activity of the intrarenal renin-angiotensin-aldosterone system, which conceptually could contribute to elevated salt sensitivity and blood pressure (BP). Our aim was to determine whether there was increased angiotensin II type 1 receptor (AT<SUB>1</SUB>R)-mediated upregulation of expression or activity of the bumetanide-sensitive Na-K-2Cl cotransporter, the thiazide-sensitive Na-Cl cotransporter (NCC), and/or the epithelial sodium channel (ENaC) in obese vs. lean Zucker rats. Male obese and lean Zucker rats (10-wk old) were fed either <I>1</I>) control chow (1% NaCl) or <I>2</I>) chow with candesartan (CAN), an AT<SUB>1</SUB>R antagonist (25 mg/kg&middot;diet) for 14 wk (<I>n</I> = 8/treatment/body type). BP measured by radiotelemetry, was markedly reduced by CAN (~20&ndash;25 mmHg) in both lean and obese rats with no body-type differences. Obese rats had significantly greater net natriuretic response to single injections of hydrochlorothiazide and benzamil, suggesting increased activity of NCC and ENaC, respectively; however, only the response to benzamil was reduced by CAN. CAN led to a significant reduction in whole kidney levels of NCC and -ENaC (70-kDa band) in both lean and obese rats. However, it significantly increased -ENaC and Na-K-2Cl cotransporter levels, and these increases were greater in obese rats. These studies suggest that relatively increased ENaC, but not NCC activity, in obese rats is due to enhanced AT<SUB>1</SUB>R activity. CAN attenuated the reduction of several renal transporters in the obese rat kidney. Finally, differences in intrarenal AT<SUB>1</SUB>R activity do not seem directly responsible for BP differences between lean and obese rats.</P>
]]></description>
<dc:creator><![CDATA[Madala Halagappa, V. K., Tiwari, S., Riazi, S., Hu, X., Ecelbarger, C. M.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00604.2007</dc:identifier>
<dc:title><![CDATA[Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1231</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1222</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1232?rss=1">
<title><![CDATA[Mechanisms underlying the long-term regulation of NHE3 by parathyroid hormone]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1232?rss=1</link>
<description><![CDATA[ 
<P>The activity of the Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger NHE3 is regulated by a number of factors including parathyroid hormone (PTH). In the current study, we used a renal epithelial cell line, the opossum kidney (OKP) cell, to elucidate the mechanisms underlying the long-term effects of PTH on NHE3 transport activity and expression. We observed that NHE3 activity was reduced 6 h after addition of PTH, and this reduction persisted almost unaltered after 24 h. The decrease in activity was associated with diminished NHE3 cell surface expression at 6, 16, and 24 h after PTH addition, total cellular NHE3 protein at 16 and 24 h, and NHE3 mRNA abundance at 24 h. The lower levels of NHE3 mRNA were associated to a small, but significant, decrease in mRNA stability. Additionally, by analyzing the rat NHE3 gene promoter activity in OKP cells, we verified that the regulatory region spanning the segment &ndash;152 to +55 was mildly reduced under the influence of PTH. This effect was completely abolished by the presence of the PKA inhibitor KT 5720. In conclusion, long-term exposure to PTH results in reduction of NHE3 mRNA levels due to a PKA-dependent inhibitory effect on the NHE3 promoter and a small reduction of mRNA half-life, and decrease in the total amount of protein which is preceded by endocytosis of the apical surface NHE3. The decreased NHE3 expression is likely to be responsible for the reduction of sodium, bicarbonate, and fluid reabsorption in the proximal tubule consistently perceived in experimental models of PTH disorders.</P>
]]></description>
<dc:creator><![CDATA[Bezerra, C. N. A., Girardi, A. C. C., Carraro-Lacroix, L. R., Reboucas, N. A.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00025.2007</dc:identifier>
<dc:title><![CDATA[Mechanisms underlying the long-term regulation of NHE3 by parathyroid hormone]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1237</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1232</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1238?rss=1">
<title><![CDATA[Mesenchymal transition in kidney collecting duct epithelial cells]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1238?rss=1</link>
<description><![CDATA[ 
<P>Progressive organ damage due to tissue scarring and fibrosis is a paradigm shared by numerous human diseases including chronic kidney disease. The purpose of this study was to confirm the hypothesis that collecting duct (CD) epithelial cells can undergo mesenchymal transition (EMT) in vitro. The mechanism by which CDs undergo EMT is complex and involves both early and late cellular events. Early events include rapid insulin-like growth factor (IGF)-induced Akt and GSK-3&beta; phosphorylation, associated with early disruption of E-cadherin-&beta;-catenin membrane colocalization, with translocation of E-cadherin to endosomes, with translocation of &beta;-catenin to the nucleus, and with an increase in Snail expression. Transforming growth factor-&beta;1, on the other hand, induced early activation of Smad3 and its translocation to the nucleus, Erk1/2 phosphorylation, and early disruption of membrane E-cadherin localization. The late consequences of these events included a phenotypic transformation of the cells to a mesenchymal morphology with associated increase in vimentin and -smooth muscle actin protein expression and a decrease in total cellular E-cadherin expression, detectable as early as 24 h after stimulation.</P>
]]></description>
<dc:creator><![CDATA[Ivanova, L., Butt, M. J., Matsell, D. G.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00326.2007</dc:identifier>
<dc:title><![CDATA[Mesenchymal transition in kidney collecting duct epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1248</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1238</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1249?rss=1">
<title><![CDATA[Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1249?rss=1</link>
<description><![CDATA[ 
<P>Diabetic nephropathy (DN) can be delayed by the use of angiotensin-converting enzyme inhibitors (ACEi). The mechanisms of ACEi renal protection are not univocal. To investigate the impact of bradykinin B<SUB>2</SUB> receptor (B2R) activation during ACE inhibition, type II diabetic mice (C57BLKS <I>db/db</I>) received for 20 wk: <I>1</I>) ACEi (ramipril) alone, <I>2</I>) ACEi + HOE-140 (a specific B2R antagonist), <I>3</I>) HOE-140 alone, or <I>4</I>) no treatment. The development of DN, defined by an increase in albuminuria and glomerulosclerosis, was largely prevented by ACEi treatment (albuminuria: 980 &plusmn; 130 vs. 2,160 &plusmn; 330 mg/g creatinine; mesangial area: 22.5 &plusmn; 0.5 vs. 27.6 &plusmn; 0.3%). The protective effect of ramipril was markedly attenuated by B2R blockade (albuminuria: 2,790 &plusmn; 680 mg/g creatinine; mesangial area: 30.4 &plusmn; 1.1%), whereas HOE-140 alone significantly increased albuminuria. Despite such benefits, glomerular filtration rate remained unchanged, probably because of the combination of the hypotensive effect of diabetes in this model and the renal hemodynamic action of ramipril. Finally, the renal protective effect of ACEi was associated with a marked decrease in glomerular overexpression of insulin-like growth factor-1 (IGF-1) and transforming growth factor-&beta; pathways, but also in advanced glycation end product receptors and lipid peroxidation assessed by 4-hydroxy-2-nonenal (4-HNE) adducts. Concomitant blockade of B2R partly restored glomerular overexpression of IGF-1 receptor &beta; and 4-HNE complexes. These results support the critical role of B2R activation in the mediation of ACEi renal protection against DN and provide the rationale to examine the benefit of B2R activation by itself as a new therapeutic approach for DN.</P>
]]></description>
<dc:creator><![CDATA[Buleon, M., Allard, J., Jaafar, A., Praddaude, F., Dickson, Z., Ranera, M.-T., Pecher, C., Girolami, J.-P., Tack, I.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00501.2007</dc:identifier>
<dc:title><![CDATA[Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1256</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1249</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1257?rss=1">
<title><![CDATA[Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA]]></title>
<link>http://ajprenal.physiology.org/cgi/content/abstract/294/5/F1257?rss=1</link>
<description><![CDATA[ 
<P>We recently reported that urinary excretion rates of angiotensinogen provide a specific index of the intrarenal renin-angiotensin system status in angiotensin II-dependent hypertensive rats. Angiotensinogen concentrations in mouse plasma are thought to be much lower than those in rat plasma; however, detailed information is deficient due to lack of direct quantitative measurements of rodent angiotensinogen. To elucidate this issue, we have developed a quantitative method for measurement of rodent angiotensinogen using a sandwich-type ELISA. The standard curve for mouse and rat angiotensinogen exhibited a high linearity at 0.16&ndash;10 and 0.08&ndash;5 ng/ml, respectively, with correlation coefficients &gt;0.99. While plasma angiotensinogen concentrations of male high serum IgA (HIGA) mice (IgA nephritis model animals, 1,308 &plusmn; 47 ng/ml; <I>n</I> = 10) were lower than those of control BALB/c mice (1,620 &plusmn; 384; <I>n</I> = 12), urinary angiotensinogen concentrations of HIGA mice (14.6 &plusmn; 1.5 ng/ml; <I>n</I> = 34) were higher than those of BALB/c mice (4.6 &plusmn; 0.1; <I>n</I> = 2). In a similar manner, while plasma angiotensinogen concentrations of Zucker diabetic fatty (ZDF) obese rats (type 2 diabetic model animals, 1,789 &plusmn; 50 ng/ml; <I>n</I> = 5) were lower than those of control ZDF lean rats (2,296 &plusmn; 47; <I>n</I> = 5), urinary angiotensinogen concentrations of ZDF obese rats (88.2 &plusmn; 11.4 ng/ml; <I>n</I> = 15) were higher than those of ZDF lean rats (31.3 &plusmn; 1.9; <I>n</I> = 15). These data indicate that plasma and urinary angiotensinogen concentrations are less in mice than rats. However, these data suggest that urinary angiotensinogen levels are different from plasma angiotensinogen levels in rodents. The development of rodent angiotensinogen ELISA allows quantitative comparisons in mouse and rat angiotensinogen levels in models of hypertension and cardiovascular and kidney diseases.</P>
]]></description>
<dc:creator><![CDATA[Kobori, H., Katsurada, A., Miyata, K., Ohashi, N., Satou, R., Saito, T., Hagiwara, Y., Miyashita, K., Navar, L. G.]]></dc:creator>
<dc:date>2008-05-01</dc:date>
<dc:identifier>info:doi/10.1152/ajprenal.00588.2007</dc:identifier>
<dc:title><![CDATA[Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>294</prism:volume>
<prism:endingPage>F1263</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>F1257</prism:startingPage>
<prism:section>INNOVATIVE METHODOLOGYS</prism:section>
</item>

</rdf:RDF>